Idelalisib: Targeting the PI3 kinase pathway in non-Hodgkin lymphoma

Cancer Journal (United States)

Volumn 22, Issue 1, 2016, Pages 12-16

  Sujobert, Pierre ^a,b,c   Rioufol, Catherine ^a,b   Salles, Gilles A ^a,b,c  

^a UNIVERSITÉ LYON 1   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

^c CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

Author keywords

Antigen; antineoplastic agents; B cell receptors; class IA phosphatidylinositol 3 kinase; non Hodgkin lymphoma

Indexed keywords

BENDAMUSTINE; BRUTON TYROSINE KINASE INHIBITOR; CARBAMAZEPINE; CORTICOSTEROID; DIPHENHYDRAMINE; ENTOSPLETINIB; EVEROLIMUS; IDELALISIB; LENALIDOMIDE; PHENYTOIN; PHOSPHATIDYLINOSITOL 3 KINASE; RIFAMPICIN; RITUXIMAB; STEROID; ANTINEOPLASTIC AGENT; ISOENZYME; PURINE DERIVATIVE; QUINAZOLINONE DERIVATIVE;

ABDOMINAL PAIN; B CELL LYMPHOMA; CANCER RECURRENCE; CHILL; CHRONIC LYMPHATIC LEUKEMIA; COLITIS; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEVER; HUMAN; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; HYPERTRIGLYCERIDEMIA; INDOLENT LYMPHOMA; LIVER FAILURE; LYMPHOMA; MANTLE CELL LYMPHOMA; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; RASH; REVIEW; TREATMENT RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; DRUG INTERACTION; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; METABOLISM; MOLECULARLY TARGETED THERAPY; RECURRENT DISEASE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; HUMANS; ISOENZYMES; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; MOLECULAR TARGETED THERAPY; PHOSPHATIDYLINOSITOL 3-KINASES; PURINES; QUINAZOLINONES; RECURRENCE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84957614333     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0000000000000167     Document Type: Review

References (37)

1. Fruman DA, Rommel C,. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov. 2014; 13: 140-156.
2. Vanhaesebroeck B, Leevers SJ, Ahmadi K, Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem. 2001; 70: 535-602.
3. Sabatini DM,. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer. 2006; 6: 729-734.
4. Samuels Y, Ericson K,. Oncogenic PI3K and its role in cancer. Curr Opin Oncol. 2006; 18: 77-82.
5. Song MS, Salmena L, Pandolfi PP,. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012; 13: 283-296.
6. Davis RE, Ngo VN, Lenz G, Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010; 463: 88-92.
7. Fukao T, Koyasu S,. PI3K and negative regulation of TLR signaling. Trends Immunol. 2003; 24: 358-363.
8. Niedermeier M, Hennessy BT, Knight ZA, Isoform-selective phosphoinositide 3′-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood. 2009; 113: 5549-5557.
9. Young RM, Staudt LM,. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov. 2013; 12: 229-243.
10. Parsonnet J, Hansen S, Rodriguez L, Helicobacter pylori infection and gastric lymphoma. N Engl J Med. 1994; 330: 1267-1271.
11. Dühren-von Minden M, Übelhart R, Schneider D, Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature. 2012; 489: 309-312.
12. Linley A, Krysov S, Ponzoni M, Lectin binding to surface Ig variable regions provides a universal persistent activating signal for follicular lymphoma cells. Blood. 2015; 126: 1902-10.
13. Billottet C, Grandage VL, Gale RE, A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene. 2006; 25: 6648-6659.
14. Sujobert P, Bardet V, Cornillet-Lefebvre P, Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood. 2005; 106: 1063-1066.
15. Lannutti BJ, Meadows SA, Herman SE, CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011; 117: 591-594.
16. Hoellenriegel J, Meadows SA, Sivina M, The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011; 118: 3603-3612.
17. Meadows SA, Vega F, Kashishian A, PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood. 2012; 119: 1897-1900.
18. Ali K, Soond DR, Piñeiro R, Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer. Nature. 2014; 510: 407-411.
19. Okkenhaug K, Bilancio A, Farjot G, Impaired B and T cell antigen receptor signaling in p110delta PI3-kinase mutant mice. Science. 2002; 297: 1031-1034.
20. Ramanathan S, Jin F, Sharma S, Clinical pharmacokinetic and pharmacodynamic 3profile of idelalisib [published online ahead of print August 5, 2015]. Clin Pharmacokinet. 2015.
21. Flinn IW, Kahl BS, Leonard JP, Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 2014; 123: 3406-13.
22. Kahl BS, Spurgeon SE, Furman RR, A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood. 2014; 123: 3398-3405.
23. Jin F, Robeson M, Zhou H, The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment. J Clin Pharmacol. 2015; 55: 944-52.
24. Jin F, Sharma S, Zhou H, Effect of acid reducing agents on the pharmacokinetics of idelalisib, a novel PI3Kδ inhibitor, in patients with hematologic malignancies S83. In Poster Session II. Clin Pharmacol Ther. 2015; 97 (suppl 1): S60-S96.
25. Brown JR, Byrd JC, Coutre SE, Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014; 123: 3390-7.
26. Gopal AK, Kahl BS, de Vos S, PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014; 370: 1008-18.
27. Gopal AK, Kahl BS, de Vos S, Mature follow up from a phase 2 study of PI3K-delta inhibitor idelalisib in patients with double (rituximab and alkylating agent)-refractory indolent B-cell non-Hodgkin lymphoma (iNHL). Blood. 2014; 124: 1708-1708.
28. Coutré SE, Barrientos JC, Brown JR, Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma. 2015; 56: 2779-86.
29. Iyengar S, Clear A, Bödör C, P110-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse. Blood. 2013; 121: 2274-84.
30. Sehn LH, Gascoyne RD,. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2015; 125: 22-32.
31. Liu JT, Kenney T, Butterworth L, Idelalisib has activity at clinically achievable drug concentrations in a subset of ABC and GCB diffuse large B-cell lymphoma and transformed follicular lymphoma cell lines. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; April 18-22, 2015; Philadelphia, PA. Philadelphia, PA: AACR.; Cancer Res. 2015; 75 (15 suppl): abstract nr 267.
32. Kahl BS, Byrd JC, Flinn IW, Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110δ in patients with relapsed or refractory non-Hodgkin lymphoma. Blood. 2010; 116: 1777-1777.
33. de Vos S, Wagner-Johnston ND, Coutre S, Durable responses following treatment with the PI3K-delta inhibitor idelalisib in combination with rituximab, bendamustine, or both, in recurrent indolent non-Hodgkin lymphoma: phase I/II results. Blood. 2014; 124: 3063-3063.
34. Wagner-Johnston ND, De Vos S, Leonard JP, Preliminary results of PI3Kδ inhibitor idelalisib (GS-1101) treatment in combination with everolimus, bortezomib, or bendamustine/rituximab in patients with previously treated mantle cell lymphoma (MCL). J Clin Oncol. 2013; 31. (suppl; abstr 8501).
35. Barr PM, Saylors GB, Spurgeon SE, Phase 2 trial of GS-9973, a selective syk inhibitor, and idelalisib (idela) in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). J Clin Oncol. 32:5s, 2014 (suppl; abstr 7059).
36. Smith SM, Pitcher B, Jung S-H, Unexpected and serious toxicity observed with combined idelalisib, lenalidomide and rituximab in relapsed/refractory B cell lymphomas: alliance A051201 and A051202. Blood. 2014; 124: 3091.
37. Cheah CY, Nastoupil LJ, Neelapu SS, Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma. Blood. 2015; 125: 3357-3359.